The effect of radiolabeled nanostructured lipid carrier systems containing imatinib mesylate on NIH-3T3 and CRL-1739 cells

The aim of current study is to develop new nanostructured lipid carrier systems (NLCSs) containing imatinib mesylate (IMT) and evaluate their targeting efficiency on NIH-3T3 as fibroblast cells and CRL-1739 as gastric adenocarcinoma cells with radiolabeled formulations. Three formulations (F1-IMT, F2-IMT and F3-IMT) were prepared and radiolabeled with 1 mCi/0.1 mL of [Tc-99m]Tc. The effect of reducing and antioxidant agents on radiolabeling process was evaluated and radiochemical purity of formulations was performed by radio thin-layer radiochromatography (RTLC). The results demonstrated that the radiochemical purity was found to be above 90% for [Tc-99m]Tc-F1-IMT and [Tc-99m]Tc-F2-IMT, while radiochemical purity of [Tc-99m]Tc-F3-IMT was found to be 85.61 +/- 2.24%. Also, [Tc-99m]Tc-F1-IMT and [Tc-99m]Tc-F2-IMT have better stability in cell medium and saline than [Tc-99m]Tc-F3-IMT. Targeting efficiency of [Tc-99m]Tc-F1-IMT and [Tc-99m]Tc-F2-IMT comparatively evaluated by cell binding studies with [Tc-99m]NaTcO4 on NIH-3T3 and CRL-1739 cells. The cell binding capacity and targeting/non-targeting cell uptake ratio of these two formulations was found to be higher than [Tc-99m]NaTcO4 in CRL-1739. It is thought that the knowledge achieved in this study would contribute to using [Tc-99m]Tc-F1-IMT and [Tc-99m]Tc F2-IMT as an diagnosis and treatment agents.